Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study
Dermatology · 2024
DOI: 10.1159/000540590 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Dermatology, 2024. Verfasst von Jeivicaa Thevan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland, jeivicaa.thevan@uzh.ch. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Pemphigoid, Bullous, Pruritus. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Dupilumab has emerged as a promising treatment option for bullous pemphigoid (BP). Rapid identification of responders could avoid the need for additional immunosuppressive treatments that are associated with increased morbidity and mortality.
Methods
To investigate the course of itch as an early indicator of treatment response, data of 12 BP patients treated with dupilumab at the University Hospital of Zurich were retrospectively evaluated. Disease severity was assessed by bullous pemphigoid disease area index (BPDAI) and pruritus by a numeric rating scale (NRS, 0–10) at baseline; days 1, 3, 14; months 1, 2; and the last follow-up.
Results
A total of 8/12 patients (67%) had complete response, and 4/12 patients (33%) had partial response during dupilumab treatment. Notably, a highly significant reduction of pruritus (p < 0.0001) was observed already on day 1 with further improvement at later time points. Moreover, fast relief of itch could predict treatment response with a significant correlation to clinical response on day 14 (Spearman correlation R 0.70, p value 0.025), with a positive but non-significant trend on day 3 (R 0.63, p value 0.091). Additionally, 92% (11/12 patients) were on dupilumab monotherapy at the last follow-up without any concomitant systemic or topical treatment for BP.
Conclusions
The rapid and significant decline in BP-associated pruritus observed with dupilumab correlated significantly with disease remission. Early evaluation of pruritus response could change how BP is treated in the future and avoid additional immunosuppressive treatment in BP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland, jeivicaa.thevan@uzh.ch.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland.
- Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
- Department of Immunology, University Hospital Zurich, Zurich, Switzerland.
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Zitieren
APA
Thevan, J., Schmauch, E., Nilsson, J., Guillet, C. F., Boesch, A., Krähenbühl, L., Meier-Schiesser, B., Schmid-Grendelmeier, P., Kündig, T., & Kolios, A. G. A. (2024). Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study. Dermatology. https://doi.org/10.1159/000540590
Vancouver
Thevan J, Schmauch E, Nilsson J, Guillet CF, Boesch A, Krähenbühl L, et al. Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study. Dermatology. 2024. doi:10.1159/000540590
BibTeX
@article{Thevan2024,
author = {Thevan, Jeivicaa and Schmauch, Eloi and Nilsson, Jakob and Guillet, Carole Florence and Boesch, Andrea and Krähenbühl, Lukas and Meier-Schiesser, Barbara and Schmid-Grendelmeier, Peter and Kündig, Thomas and Kolios, Antonios G A},
title = {Fast Itch Relief during Dupilumab Predicts Clinical Efficacy in Bullous Pemphigoid: A Retrospective Cohort Study},
journal = {Dermatology},
year = {2024},
doi = {10.1159/000540590}
}
EUVIMED